Thyrocare Technologies Ltd
NSE:THYROCARE

Watchlist Manager
Thyrocare Technologies Ltd Logo
Thyrocare Technologies Ltd
NSE:THYROCARE
Watchlist
Price: 956.15 INR -1.4% Market Closed
Market Cap: 50.6B INR
Have any thoughts about
Thyrocare Technologies Ltd?
Write Note

Thyrocare Technologies Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Thyrocare Technologies Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Thyrocare Technologies Ltd
NSE:THYROCARE
Total Liabilities & Equity
â‚ą6.4B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Dr Agarwal's Eye Hospital Ltd
BSE:526783
Total Liabilities & Equity
â‚ą5B
CAGR 3-Years
47%
CAGR 5-Years
38%
CAGR 10-Years
22%
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Total Liabilities & Equity
â‚ą26B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
Total Liabilities & Equity
â‚ą8.5B
CAGR 3-Years
16%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Krsnaa Diagnostics Ltd
NSE:KRSNAA
Total Liabilities & Equity
â‚ą11.7B
CAGR 3-Years
25%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Metropolis Healthcare Ltd
NSE:METROPOLIS
Total Liabilities & Equity
â‚ą15.6B
CAGR 3-Years
16%
CAGR 5-Years
23%
CAGR 10-Years
N/A
No Stocks Found

Thyrocare Technologies Ltd
Glance View

Market Cap
50.6B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
585.36 INR
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Thyrocare Technologies Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
6.4B INR

Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Total Liabilities & Equity amounts to 6.4B INR.

What is Thyrocare Technologies Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
6%

Over the last year, the Total Liabilities & Equity growth was 2%. The average annual Total Liabilities & Equity growth rates for Thyrocare Technologies Ltd have been 6% over the past three years , 6% over the past five years .

Back to Top